BillionToOne Integrates Prenatal and Oncology Tests into Epic’s EHR to Drive Adoption and Workflow Efficiency

New updates have been reported about BillionToOne.

BillionToOne has signed an agreement with Epic to integrate its UNITY Complete prenatal test and Northstar liquid biopsy oncology assays into Epic’s Aura diagnostics suite, embedding the company’s core products directly into the most widely used U.S. electronic health record system. Clinicians using Epic will be able to order UNITY Complete, Northstar Select, and Northstar Response from within their existing workflow, with structured results flowing back into the patient record and into MyChart for patient access. This integration is designed to reduce ordering friction, standardize reporting, and support clinical decision support tools across health systems, community practices, maternal-fetal medicine groups, and oncology clinics, potentially accelerating test adoption and volume for BillionToOne.

For BillionToOne, the Epic collaboration is a strategic distribution and access play for its prenatal and oncology portfolios rather than a technology shift, positioning UNITY Complete—the only clinically validated non-invasive prenatal test offering direct fetal risk assessment for up to 14 recessive and X-linked conditions plus aneuploidies—and the Northstar tests more prominently at the point of care. By being embedded in Epic’s workflow, the company aims to capture incremental demand from clinicians who prefer integrated ordering and result management, support faster treatment and pregnancy management decisions, and strengthen its value proposition to large health systems. Management notes that expectations for increased test adoption and operational benefits remain subject to execution and typical implementation risks, including the possibility that the Epic integration does not translate into higher utilization, as outlined in the company’s SEC risk disclosures. Overall, the move signals BillionToOne’s intent to scale its commercial reach through health IT integration, improve provider and patient experience, and reinforce its competitive position in both prenatal screening and oncology diagnostics.